GlassScriptPhysician profile
Frederick D Jenkin
NPI 1225069123
$7,633.51
in general payments reported to CMS, 2019-2025
31 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $717 · 2021: $281 · 2022: $548 · 2023: $503 · 2024: $1,252 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,453 · Education: $9.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,453.15 |
| Education | $9.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $923.98 | 2019-2024 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $892.96 | 2019-2022 | |
| Lilly USA, LLC | $545.44 | 2020-2024 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $476.97 | 2023-2024 | Rexulti |
| Abbvie INC. | $467.68 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $441.70 | 2019-2020 | |
| Alkermes, INC. | $345.84 | 2022-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $324.10 | 2024-2025 | Fanapt |
| Acadia Pharmaceuticals INC | $298.14 | 2019-2025 | Nuplazid |
| Beone Medicines USA, INC. | $281.89 | 2025 | Brukinsa |
| Ucb, INC. | $250.00 | 2025 | Fintepla, Nayzilam |
| Incyte Corporation | $248.82 | 2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $247.93 | 2025 | Carvykti, Rybrevant |
| Neurocrine Biosciences, INC. | $163.70 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $143.25 | 2025 | Kabiven |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136.53 | 2024 | Arexvy |
| Mylan Specialty L.P. | $124.91 | 2019 | |
| Allergan, INC. | $124.32 | 2020 | |
| Csl Behring | $124.26 | 2025 | Hizentra |
| Daiichi Sankyo INC. | $124.25 | 2025 | Datroway |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.12 | 2019 | |
| Alnylam Pharmaceuticals INC. | $122.84 | 2024 | Amvuttra |
| Eisai INC. | $122.25 | 2022 | |
| Amgen INC. | $121.84 | 2025 | Evenity |
| Astellas Pharma US INC | $121.84 | 2025 | Xospata |
| Novo Nordisk INC | $121.36 | 2025 | Ozempic |
| Amarin Pharma, INC. | $119.56 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $76.22 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.81 | 2025 | Caplyta |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Jenkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.